Literature DB >> 10623372

Socioeconomic evaluation in medicine in Europe. Core economic concepts.

K Berger1, T D Szucs.   

Abstract

In most European countries, healthcare cost-containment programmes have failed to meet their targets on a long term basis. For this reason, decision-makers sought effective and rational strategies to assist in the optimal allocation of available resources. The scholarly discipline of economics provides methods and instruments for investigating the rational use of limited resources. In the context of these efforts, socioeconomic evaluations of healthcare programmes have become increasingly important during the last decade. A socioeconomic evaluation is an analysis of all costs and consequences over a relevant time-period for a particular healthcare intervention. For example, a socioeconomic evaluation of an influenza prevention programme should consider the total costs of preventing influenza (costs of the vaccine, vaccination programme and treatment of adverse events), as well as the benefits of such a programme (costs saved as a result of cases of influenza avoided). In general, socioeconomic evaluations usually compare costs and benefits relative to alternative treatment strategies. The core concepts of socioeconomic analyses are as follows: costs and consequences, discounting, marginal and incremental costs, and externalities (spill-over effects). All these concepts are fixed components of published guidelines and should be considered when conducting a socioeconomic evaluation.

Mesh:

Year:  1999        PMID: 10623372     DOI: 10.2165/00019053-199916001-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

Review 1.  Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.

Authors:  J E Siegel; G W Torrance; L B Russell; B R Luce; M C Weinstein; M R Gold
Journal:  Pharmacoeconomics       Date:  1997-02       Impact factor: 4.981

Review 2.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

3.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

Review 4.  A comparative review of pharmacoeconomic guidelines.

Authors:  P Jacobs; J Bachynsky; J F Baladi
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

5.  Estimating costs in the economic evaluation of medical technologies.

Authors:  B R Luce; A Elixhauser
Journal:  Int J Technol Assess Health Care       Date:  1990       Impact factor: 2.188

Review 6.  Discounting the future: influence of the economic model.

Authors:  R R West
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

7.  Discounting costs and effects: a reconsideration.

Authors:  B A van Hout
Journal:  Health Econ       Date:  1998-11       Impact factor: 3.046

Review 8.  Clinical economics. A guide to the economic analysis of clinical practices.

Authors:  J M Eisenberg
Journal:  JAMA       Date:  1989-11-24       Impact factor: 56.272

9.  Herd immunity: basic concept and relevance to public health immunization practices.

Authors:  J P Fox; L Elveback; W Scott; L Gatewood; E Ackerman
Journal:  Am J Epidemiol       Date:  1971-09       Impact factor: 4.897

Review 10.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

Authors:  A Briggs; M Sculpher; M Buxton
Journal:  Health Econ       Date:  1994 Mar-Apr       Impact factor: 3.046

View more
  1 in total

1.  Cost-benefit analysis of influenza vaccination in a public healthcare unit.

Authors:  Giorgio L Colombo; Antonio Ferro; Marta Vinci; Maria Zordan; Giulio Serra
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.